|
|
Article: Updated labeling for Soriatane (acitretin) for psoriasis.(Pipeline Previews)(Brief Article)
- Article from:
- Journal of Drugs in Dermatology
- Article date:
- October 1, 2003
CopyrightCOPYRIGHT 2003 Journal of Drugs in Dermatology, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Soriatane[R] (acitretin), a systemic medication for severe psoriasis, has received approval for an enhanced product labeling.
The major changes to the label include:
-Information regarding reducing phototherapy dose in patients concurrently using Soriatane
-Clarification of dosing schedule. The recommended initial dose has been changed to 25 mg to 50 mg per day, rather than 25 mg or 50 mg. The availability of 10 mg and 25 mg capsules gives prescribers the ability to adjust the dose up or down in small increments.
-Inclusion of efficacy results from clinical trials in which Soriatane was shown to be effective in five major ...